Wherefore Art Thou, O Treatment for Diabetic Neuropathy?

Research output: Chapter in Book/Report/Conference proceedingConference contribution

13 Citations (Scopus)

Abstract

As of March 2016, we continue to advocate the diagnosis of diabetic neuropathy using a simple foot examination or monofilament, which identifies only those with severe neuropathy and hence risk of foot ulceration. Given the fact that the 5-year mortality rate of diabetic patients with foot ulceration is worse than that of most common cancers, surely we should be identifying patients at an earlier stage of neuropathy to prevent its progression to a stage with such a high mortality? Of course, we lament that there is no licensed treatment for diabetic neuropathy. Who is to blame? As researchers and carers, we have a duty of care to our patients with diabetic neuropathy. So, we have to look forward not backwards, and move away from our firmly entrenched views on the design and conduct of clinical trials for diabetic neuropathy. Relevant organizations such as Neurodiab, the American Diabetes Association and the Peripheral Nerve Society have to acknowledge that they cannot continue to endorse a bankrupt strategy. The FDA needs an open and self-critical dialogue with these organizations, to give pharmaceutical companies at least a fighting chance to deliver effective new therapies for diabetic neuropathy.

Original languageEnglish
Title of host publicationControversies In Diabetic Neuropathy, 2016
PublisherAcademic Press Inc.
Pages287-317
Number of pages31
Volume127
ISBN (Print)9780128039151
DOIs
Publication statusPublished - 2016

Publication series

NameInternational Review of Neurobiology
Volume127
ISSN (Print)00747742

Fingerprint

Diabetic Neuropathies
Art
Foot
Organizations
Therapeutics
Mortality
Caregivers
Research Personnel
Clinical Trials
Pharmaceutical Preparations
Neoplasms

Keywords

  • Clinical trial
  • Corneal
  • Diabetes
  • FDA
  • Neuropathy
  • Small fiber neuropathy
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Malik, R. (2016). Wherefore Art Thou, O Treatment for Diabetic Neuropathy? In Controversies In Diabetic Neuropathy, 2016 (Vol. 127, pp. 287-317). (International Review of Neurobiology; Vol. 127). Academic Press Inc.. https://doi.org/10.1016/bs.irn.2016.03.008

Wherefore Art Thou, O Treatment for Diabetic Neuropathy? / Malik, Rayaz.

Controversies In Diabetic Neuropathy, 2016. Vol. 127 Academic Press Inc., 2016. p. 287-317 (International Review of Neurobiology; Vol. 127).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Malik, R 2016, Wherefore Art Thou, O Treatment for Diabetic Neuropathy? in Controversies In Diabetic Neuropathy, 2016. vol. 127, International Review of Neurobiology, vol. 127, Academic Press Inc., pp. 287-317. https://doi.org/10.1016/bs.irn.2016.03.008
Malik R. Wherefore Art Thou, O Treatment for Diabetic Neuropathy? In Controversies In Diabetic Neuropathy, 2016. Vol. 127. Academic Press Inc. 2016. p. 287-317. (International Review of Neurobiology). https://doi.org/10.1016/bs.irn.2016.03.008
Malik, Rayaz. / Wherefore Art Thou, O Treatment for Diabetic Neuropathy?. Controversies In Diabetic Neuropathy, 2016. Vol. 127 Academic Press Inc., 2016. pp. 287-317 (International Review of Neurobiology).
@inproceedings{982921440c014d08888dc9fabb5f500e,
title = "Wherefore Art Thou, O Treatment for Diabetic Neuropathy?",
abstract = "As of March 2016, we continue to advocate the diagnosis of diabetic neuropathy using a simple foot examination or monofilament, which identifies only those with severe neuropathy and hence risk of foot ulceration. Given the fact that the 5-year mortality rate of diabetic patients with foot ulceration is worse than that of most common cancers, surely we should be identifying patients at an earlier stage of neuropathy to prevent its progression to a stage with such a high mortality? Of course, we lament that there is no licensed treatment for diabetic neuropathy. Who is to blame? As researchers and carers, we have a duty of care to our patients with diabetic neuropathy. So, we have to look forward not backwards, and move away from our firmly entrenched views on the design and conduct of clinical trials for diabetic neuropathy. Relevant organizations such as Neurodiab, the American Diabetes Association and the Peripheral Nerve Society have to acknowledge that they cannot continue to endorse a bankrupt strategy. The FDA needs an open and self-critical dialogue with these organizations, to give pharmaceutical companies at least a fighting chance to deliver effective new therapies for diabetic neuropathy.",
keywords = "Clinical trial, Corneal, Diabetes, FDA, Neuropathy, Small fiber neuropathy, Treatment",
author = "Rayaz Malik",
year = "2016",
doi = "10.1016/bs.irn.2016.03.008",
language = "English",
isbn = "9780128039151",
volume = "127",
series = "International Review of Neurobiology",
publisher = "Academic Press Inc.",
pages = "287--317",
booktitle = "Controversies In Diabetic Neuropathy, 2016",
address = "United States",

}

TY - GEN

T1 - Wherefore Art Thou, O Treatment for Diabetic Neuropathy?

AU - Malik, Rayaz

PY - 2016

Y1 - 2016

N2 - As of March 2016, we continue to advocate the diagnosis of diabetic neuropathy using a simple foot examination or monofilament, which identifies only those with severe neuropathy and hence risk of foot ulceration. Given the fact that the 5-year mortality rate of diabetic patients with foot ulceration is worse than that of most common cancers, surely we should be identifying patients at an earlier stage of neuropathy to prevent its progression to a stage with such a high mortality? Of course, we lament that there is no licensed treatment for diabetic neuropathy. Who is to blame? As researchers and carers, we have a duty of care to our patients with diabetic neuropathy. So, we have to look forward not backwards, and move away from our firmly entrenched views on the design and conduct of clinical trials for diabetic neuropathy. Relevant organizations such as Neurodiab, the American Diabetes Association and the Peripheral Nerve Society have to acknowledge that they cannot continue to endorse a bankrupt strategy. The FDA needs an open and self-critical dialogue with these organizations, to give pharmaceutical companies at least a fighting chance to deliver effective new therapies for diabetic neuropathy.

AB - As of March 2016, we continue to advocate the diagnosis of diabetic neuropathy using a simple foot examination or monofilament, which identifies only those with severe neuropathy and hence risk of foot ulceration. Given the fact that the 5-year mortality rate of diabetic patients with foot ulceration is worse than that of most common cancers, surely we should be identifying patients at an earlier stage of neuropathy to prevent its progression to a stage with such a high mortality? Of course, we lament that there is no licensed treatment for diabetic neuropathy. Who is to blame? As researchers and carers, we have a duty of care to our patients with diabetic neuropathy. So, we have to look forward not backwards, and move away from our firmly entrenched views on the design and conduct of clinical trials for diabetic neuropathy. Relevant organizations such as Neurodiab, the American Diabetes Association and the Peripheral Nerve Society have to acknowledge that they cannot continue to endorse a bankrupt strategy. The FDA needs an open and self-critical dialogue with these organizations, to give pharmaceutical companies at least a fighting chance to deliver effective new therapies for diabetic neuropathy.

KW - Clinical trial

KW - Corneal

KW - Diabetes

KW - FDA

KW - Neuropathy

KW - Small fiber neuropathy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84963976434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963976434&partnerID=8YFLogxK

U2 - 10.1016/bs.irn.2016.03.008

DO - 10.1016/bs.irn.2016.03.008

M3 - Conference contribution

SN - 9780128039151

VL - 127

T3 - International Review of Neurobiology

SP - 287

EP - 317

BT - Controversies In Diabetic Neuropathy, 2016

PB - Academic Press Inc.

ER -